Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 29 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
CROIXSSANCE PHARMA from Zaventem, company number BE0644605976, closed financial year 2025 with a result of € 1,861 after tax. For that financial year CROIXSSANCE PHARMA recorded a gross margin of € 5,783 and equity of € -15,015. Compared with financial year 2024, the result moved from € -1,801 to € 1,861. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.
€ -15,015
▲ € 1,861 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1,861
▲ still € 1,801 loss in 2024
Profit after tax over the fiscal year.
€ 1,485
▼ 84% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -33,615.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 950
▲ 70% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2,444
▼ 57% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 3,353
▲ 169% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 4,717 | € -9,896 | € 2,300 | € 5,783 | ▲ 151% |
| Profit after taxes | € 2,022 | € -13,565 | € -1,801 | € 1,861 | ▲ € 3,662 |
| Equity | € -1,511 | € -15,076 | € -16,876 | € -15,015 | ▲ € 1,861 |
| Total debts | € 14,262 | € 29,817 | € 47,731 | € 24,489 | ▼ 49% |
| Cash | € 1,993 | € 8,839 | € 9,462 | € 1,485 | ▼ 84% |
| Retained profit | € -20,111 | € -33,676 | € -35,476 | € -33,615 | ▲ € 1,861 |
| Bank debt | € 107 | € 107 | € 0 | € 0 | |
| Balance sheet total | € 12,752 | € 14,741 | € 30,855 | € 9,474 | ▼ 69% |
Key figures of CROIXSSANCE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CROIXSSANCE PHARMA?
What happened at CROIXSSANCE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1,861. Source: NBB ↗
- New establishment in Sint-Pieters-Woluwe. KBO
- Start of the company according to the CBE. KBO
In short
From € 2,022 profit in 2022 to € 1,861 profit in 2025.
Paid € 1,507 in corporate taxes since 2022.
Best year ever: 2022, with € 2,022 profit.
Management
Behind CROIXSSANCE PHARMA is Alfred DANNOURA. Alfred DANNOURA is also behind SagaCité.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Kouterlaan 99
1930 Zaventem
Jean-Baptiste Dumoulinstraat 52
1150 Sint-Pieters-Woluwe
Active since 17 December 2015
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0644.605.976
- VAT number
- BE 0644.605.976
- Registered office
- Kouterlaan 99, 1930 Zaventem
- Names & denominations
- CROIXSSANCE PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 December 2015
- Peppol
- Active · Active since 17 Jun 2024
- Activities · NACE
Detailhandel in farmaceutische producten